Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

AI in Life Sciences Market to Reach US$11.52 Billion by 2034 as Drug Discovery, Precision Medicine and Automation Drive New Business Opportunities

globenewswire.com
RXRX Mentioned as a leading company in the AI in Life Sciences market, indicating its involvement in a growing sector. No specific positive or negative news. ATOM Mentioned as a leading company in the AI in Life Sciences market, indicating its involvement in a growing sector. No specific positive or negative news. NVDA NVIDIA announced a USD 1 billion AI co-innovation laboratory with Eli Lilly, highlighting its key role in providing advanced computing infrastructure for pharmaceutical research. INTC Mentioned as a leading company in the AI in Life Sciences market, indicating its involvement in a growing sector. No specific positive or negative news. AMD Mentioned as a leading company in the AI in Life Sciences market, indicating its involvement in a growing sector. No specific positive or negative news. AMZN Mentioned as a leading company in the AI in Life Sciences market, indicating its involvement in a growing sector. No specific positive or negative news. MSFT Mentioned as a leading company in the AI in Life Sciences market, indicating its involvement in a growing sector. No specific positive or negative news. GOOG Mentioned as a leading company in the AI in Life Sciences market, indicating its involvement in a growing sector. No specific positive or negative news. IBM Mentioned as a leading company in the AI in Life Sciences market, indicating its involvement in a growing sector. No specific positive or negative news. DELL Mentioned as a leading company in the AI in Life Sciences market, indicating its involvement in a growing sector. No specific positive or negative news. ILMN Mentioned as a leading company in the AI in Life Sciences market, indicating its involvement in a growing sector. No specific positive or negative news. IQV Mentioned as a leading company in the AI in Life Sciences market, indicating its involvement in a growing sector. No specific positive or negative news. ACN Mentioned as a leading company in the AI in Life Sciences market, indicating its involvement in a growing sector. No specific positive or negative news. LLY Eli Lilly announced a USD 1 billion AI co-innovation laboratory with NVIDIA and expanded a partnership with Insilico Medicine for AI-discovered drug candidates valued up to USD 2.75 billion. ORCL Oracle launched its Life Sciences AI Data Platform to unify patient information and support generative AI analysis, indicating new product development in the AI space.

AI in Life Sciences Market to Reach US$11.52 Billion by 2034 as Drug Discovery, Precision Medicine and Automation Drive New Business Opportunities Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Artificial Intelligence (AI) in Life Sciences - Market Insights, Competitive Landscape, and Market Forecast - 2034" has been added to ResearchAndMarkets.com's offering.

The global artificial intelligence in life sciences market is projected to increase from USD 2.24 billion in 2025 to USD 11.52 billion by 2034. The market is expected to register a compound annual growth rate of 20.06% from 2026 to 2034, supported by rising demand for faster drug discovery, data-driven clinical research, precision medicine and advanced diagnostics.

Pharmaceutical and biotechnology companies are increasingly integrating artificial intelligence into research and development workflows to accelerate target identification, molecule design, virtual screening and predictive modeling. These capabilities can reduce development timelines, improve candidate selection and support more efficient use of research resources. AI adoption is also expanding across clinical trial optimization, medical imaging, biomarker discovery, laboratory automation and treatment planning.

Key Artificial Intelligence in Life Sciences Market Growth Drivers

Software is estimated to account for the largest component share in 2025. Demand is being driven by the adoption of cloud-based research platforms, generative AI models, predictive analytics and integrated data environments. Hardware and services remain important as companies invest in high-performance computing, specialized infrastructure, implementation support and regulatory compliance capabilities.

Market Segmentation and Applications

The artificial intelligence in life sciences market is analyzed by component, application, deployment model, end user, production scale and geography. Components include software, hardware and services. Major applications include drug discovery and development, clinical trial optimization, medical imaging and diagnostics, and other research or operational functions.

Deployment options include on-premises and cloud-based environments. Principal end users include pharmaceutical and biotechnology companies, contract research organizations, contract development and manufacturing organizations, and other life sciences participants. Production-scale analysis covers preclinical, clinical and commercial operations.

AI-powered innovation is influencing the full life sciences value chain. Drug developers are applying advanced models to generate and evaluate molecules, predict protein interactions and identify potential safety concerns. Clinical research organizations are using AI to analyze electronic health records and real-world data, while diagnostic providers are adopting AI-assisted imaging and decision-support technologies. Digital twins, automated laboratories and AI-driven biomarker discovery represent additional areas of opportunity.

Regional Artificial Intelligence in Life Sciences Market Outlook

North America is expected to hold approximately 44.78% of the global market in 2025. Its leadership is supported by advanced healthcare infrastructure, substantial research and development investment, early technology adoption and the strong presence of pharmaceutical, biotechnology and cloud computing companies. Access to large healthcare datasets and collaboration between technology providers and life sciences organizations further strengthens the regional market.

Recent activity underscores North America's position in AI-enabled research. Developments include investments in computational drug discovery, expansion of AI-supported clinical data platforms and growing regulatory engagement with AI applications across clinical development. In January 2026, NVIDIA and Eli Lilly announced a USD 1 billion AI co-innovation laboratory focused on accelerating pharmaceutical research through advanced computing infrastructure.

Europe is experiencing sustained growth as pharmaceutical companies, biotechnology firms and AI startups expand their collaboration. The European Health Data Space, evolving AI regulations and initiatives supporting secure cross-border data use are expected to influence adoption. Regional demand is also supported by precision medicine programs, strong academic research networks and investment in AI-enabled drug discovery and clinical trials.

Asia-Pacific is positioned as a high-growth market because of rapid digital transformation, expanding biotechnology investment and government support in China, India, Japan and South Korea. The region's large patient population, growing clinical trial activity and increasing availability of genomic and healthcare data create significant opportunities for AI platform providers. Expanding startup ecosystems and partnerships between global pharmaceutical companies and regional technology firms are also contributing to market development.

Competitive Landscape and Recent Developments

The competitive environment includes global technology companies, pharmaceutical organizations, research platform providers and specialized AI startups. Competition centers on proprietary datasets, model performance, computing capacity, platform integration and the ability to support regulated research and clinical workflows.

Leading companies include Recursion Pharmaceuticals, Insilico Medicine, Atomwise, Exscientia, BenevolentAI, NVIDIA, Medidata by Dassault Systemes, Scispot, Cyclica, Deep Genomics, Karyon Bio, Variant Bio, Intel, Advanced Micro Devices, Amazon Web Services, Microsoft, Google Cloud, IBM, Dell Technologies, CoreWeave, Illumina, IQVIA, Accenture and Cognizant.

Notable market developments reported in 2026 include the expansion of Insilico Medicine's partnership with Eli Lilly in a transaction valued at up to USD 2.75 billion for AI-discovered drug candidates. Tempus AI expanded its AI-enabled clinical data platform, while Isomorphic Labs introduced an advanced drug design engine focused on protein-ligand prediction and molecule development. Oracle also launched its Life Sciences AI Data Platform to unify real-world patient information and support generative AI analysis across research and clinical workflows.

Market Challenges and Tariff Impact

Data privacy, cybersecurity and regulatory compliance remain important barriers to adoption. Life sciences AI platforms frequently process sensitive clinical, genomic and patient information, increasing requirements for secure storage, controlled access and responsible data governance. Evolving rules for AI-enabled healthcare applications can also extend approval timelines and raise development costs.

U.S. tariffs on semiconductors, medical technology components and pharmaceutical inputs may increase the cost of GPUs, servers, data centers and other infrastructure required for AI research. Supply chain disruption could have a disproportionate impact on smaller biotechnology companies with limited capital resources. However, these pressures may also encourage domestic infrastructure investment, diversified sourcing, reshoring and greater use of AI for supply chain optimization and cost management.

Market Outlook

The artificial intelligence in life sciences market is expected to maintain strong momentum through 2034 as organizations pursue shorter development timelines, higher research productivity and improved clinical outcomes. Cloud adoption, generative AI, multi-omics analysis and real-world evidence platforms are likely to create further opportunities across preclinical research, clinical development and commercial operations.

Companies that establish secure data strategies, scalable computing environments and collaborative research ecosystems will be better positioned to capitalize on market expansion. Continued investment in validation, regulatory readiness and responsible AI governance will remain essential as artificial intelligence becomes increasingly embedded throughout the global life sciences industry.

A selection of companies mentioned in this report includes, but is not limited to:

For more information about this report visit https://www.researchandmarkets.com/r/ac3yi5

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.